TORONTO, ONTARIO–(Marketwire – Dec. 7, 2012) – Arch Biopartners Inc (“Arch” or the “Company”)(CNSX:ACH)(OTCBB:FOIFF) today announced that Arch scientists have reported results of a recent study involving Arch peptides and the role they play in reducing initial biofilm formation and surface corrosion on stainless steel.
2012
Dr. Julia Liu to Present at American College of Gastroenterology Annual Meeting Oct 22, 2012
TORONTO, ONTARIO–(Marketwire – Oct. 18, 2012) – Arch Biopartners Inc. (“Arch” or the “Company”) (CNSX:ACH)(OTCBB:FOIFF) today announced that Dr. Julia Liu will be presenting new data on the topic “Confocal Laser Endomicroscopy Findings of the Small Intestine in Irritable Bowel Syndrome (IBS) patients” at the American College of Gastroenterology’s (ACG) Annual Scientific Meeting in Las Vegas, October 19-24.
Arch Biopartners Enters Option to Acquire Irritable Bowel Syndrome Diagnostic Technology
TORONTO, ONTARIO–(Marketwire – Sept. 6, 2012) – Arch Biopartners Inc (“Arch” or the “Company”)(CNSX:ACH)(OTCBB:FOIFF) announces it has entered into an option agreement to acquire the intellectual property rights to a new diagnostic technology which identifies irritable bowel syndrome (IBS).
Arch Scientists Successfully Image Brain Tumour Initiating Cells Using MRI
TORONTO, ONTARIO–(Marketwire – Aug. 21, 2012) – Arch Biopartners Inc (“Arch”) (CNSX:ACH)(OTCBB:FOIFF) today announced Arch scientists have successfully used magnetic resonance imaging (“MRI”) to detect human brain tumour initiating cells in mice using Arch’s proprietary cell targeting technology.
Arch Awarded Funding from the Government of Canada to Develop Brain Tumour Targeting Technology
TORONTO, CANADA–(Marketwire – March 15, 2012) – Arch Biopartners Inc. (“Arch” or the “Company”) (CNSX:ACH)(OTCBB:FOIFF) today announced that the National Research Council of Canada – Industrial Research Assistance Program (NRC-IRAP) has approved funding up to $107,000 to assist Arch in the development of diagnostic imaging applications for its brain tumour initiating cell (“BTIC”) targeting technology.
Arch Scientists to Lead Anti Corrosion Project for Auto Industry
TORONTO, ONTARIO–(Marketwire – Feb. 28, 2012) – Arch Biopartners Inc. (“Arch” or the “Company”) (CNSX:ACH)(OTCBB:FOIFF) today announced that AUTO21 and its contributing partners have approved funding totaling $518,400 for Arch scientists to lead an anti corrosion project on Magnesium (“Mg”) and rare earth (“RE”) alloys for the Canadian auto industry.
Arch Biopartners Appoints Claude Allary as Special Advisor
TORONTO, ONTARIO–(Marketwire – Jan. 24, 2012) – Arch Biopartners Inc (“Arch” or the “Company”) (CNSX:ACH)(OTC:FOIFF) announced today Claude Allary has been appointed Special Advisor to the Company. In this capacity, Mr. Allary will provide expertise in evaluating commercial opportunities for the Company’s drug development platforms and other emerging technologies.